Apurinic/apyrimidinic endonuclease 1 (APE1) is a multifunctional enzyme that is involved in DNA repair and the redox regulation of transcription factors. Blocking these functions leads to cell-growth inhibition, apoptosis and other effects. Previous studies have demonstrated that high expression levels of the APE1 protein are associated with the progression and chemoresistance of cancers. We hypothesized thatAPE1 silencing in ovarian cancer cells might have anticancer effects mediated by cell-growth inhibition and an increase in drug-sensitivity.
OBJECTIVE:
In this study, we explored the consequences of APE1 silencing in ovarian cancer cells.
METHODS:
Immunohistochemistry (IHC) was used to detect the APE1 protein levels in tissue samples from twelve ovarian cancer (OC) patients and eleven non-OC patients. APE1 knockdown was achieved via the stable transfection of SKOV3 and A2780 cells with a construct encoding a short hairpin DNA directed against the APE1 gene. Then, cell proliferation, colony formation, cell cycle and apoptosis assays were performed to reveal the consequences of APE1 silencing in ovarian cancer cells. Additionally, the SKOV3 and A2780 cells were subjected to the treatment with camptothecin (CPT) and ultraviolet rays (UV) to assess the possible link between the APE1 protein and drug-resistance.
RESULTS:
Our results revealed that the APE1 protein was overexpressed in OC tissues. APE1 knockdown in A2780 and SKOV3 cells reduced cell proliferation, arrested cell cycle progression, repressed colony formation and weakly promoted cell apoptosis through the BAX and BCL-2 apoptotic pathways. Additionally, the down-regulation of APE1 significantly enhanced the sensitivity of ovarian cancer cells to the CPT/UV treatment.
CONCLUSION:
Our study suggested that the APE1 protein is important for the proliferation and growth of ovarian cancer cells. APE1 silencing might enhance drug-sensitivity, and thus APE1 might serve as a novel anti-OC therapeutic target.
SaikaK., and SobueT., Cancer statistics in the world, Gan To Kagaku Ryoho40 (2013), 2475-80.
2.
MacuksR., BaidekalnaI., and DoninaS., An ovarian cancer malignancy risk index composed of HE4, CA125, ultrasonographic score, and menopausal status: use in differentiation of ovarian cancers and benign lesions, Tumour Biol33 (2012), 1811-7.
3.
KippsE., TanD.S., and KayeS.B., Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research, Nat Rev Cancer13 (2013), 273-82.
4.
BastR.J., HennessyB., and MillsG.B., The biology of ovarian cancer: New opportunities for translation, Nat Rev Cancer9 (2009), 415-28.
5.
AlveroA.B., ChenR., FuH.H., MontagnaM., SchwartzP.E., RutherfordT., SilasiD.A., SteffensenK.D., WaldstromM., VisintinI., and MorG., Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance, Cell Cycle8 (2009), 158-66.
6.
FritzG., Human APE/Ref-1 protein, Int J Biochem Cell Biol32 (2000), 925-9.
7.
KanazhevskayaL.Y., KovalV.V., ZharkovD.O., StraussP.R., and FedorovaO.S., Conformational transitions in human AP endonuclease 1 and its active site mutant during abasic site repair, Biochemistry49 (2010), 6451-61.
8.
MolC.D., IzumiT., MitraS., and TainerJ.A., DNA-bound structures and mutants reveal abasic DNA binding by APE1 and DNA repair coordination [corrected], Nature403 (2000), 451-6.
9.
AdhikariS., ChoudhuryS., MitraP.S., DubashJ.J., SajankilaS.P., and RoyR., Targeting base excision repair for chemosensitization, Anticancer Agents Med Chem8 (2008), 351-7.
10.
MitraS., IzumiT., BoldoghI., BhakatK.K., ChattopadhyayR., and SzczesnyB., Intracellular trafficking and regulation of mammalian AP-endonuclease 1 (APE1), an essential DNA repair protein, DNA Repair (Amst)6 (2007), 461-9.
11.
TellG., QuadrifoglioF., TiribelliC., and KelleyM.R., The many functions of APE1/Ref-1: Not only a DNA repair enzyme, Antioxid Redox Signal11 (2009), 601-20.
12.
LuoM., HeH., KelleyM.R., and GeorgiadisM.M., Redox regulation of DNA repair: Implications for human health and cancer therapeutic development, Antioxid Redox Signal12 (2010), 1247-69.
13.
BapatA., FishelM.L., and KelleyM.R., Going ape as an approach to cancer therapeutics, Antioxid Redox Signal11 (2009), 651-68.
14.
LuoM., DelaplaneS., JiangA., ReedA., HeY., FishelM., NylandR.N., BorchR.F., QiaoX., GeorgiadisM.M., and KelleyM.R., Role of the multifunctional DNA repair and redox signaling protein Ape1/Ref-1 in cancer and endothelial cells: small-molecule inhibition of the redox function of Ape1, Antioxid Redox Signal10 (2008), 1853-67.
15.
KelleyM.R., and FishelM.L., DNA repair proteins as molecular targets for cancer therapeutics, Anticancer Agents Med Chem8 (2008), 417-25.
16.
HirotaK., MurataM., SachiY., NakamuraH., TakeuchiJ., MoriK., and YodoiJ., Distinct roles of thioredoxin in the cytoplasm and in the nucleus. A two-step mechanism of redox regulation of transcription factor NF-kappaB, J Biol Chem274 (1999), 27891-7.
17.
LandoD., PongratzI., PoellingerL., and WhitelawM.L., A redox mechanism controls differential DNA binding activities of hypoxia-inducible factor (HIF) 1alpha and the HIF-like factor, J Biol Chem275 (2000), 4618-27.
JiangY., ZhouS., SanduskyG.E., KelleyM.R., and FishelM.L., Reduced expression of DNA repair and redox signaling protein APE1/Ref-1 impairs human pancreatic cancer cell survival, proliferation, and cell cycle progression, Cancer Invest28 (2010), 885-95.
20.
WangM., ChuH., WangS., WangM., WangW., HanS., and ZhangZ., Genetic variant in APE1 gene promoter contributes to cervical cancer risk, Am J Obstet Gynecol209 (2013), 360-1.
21.
YooD.G., SongY.J., ChoE.J., LeeS.K., ParkJ.B., YuJ.H., LimS.P., KimJ.M., and JeonB.H., Alteration of APE1/ref-1 expression in non-small cell lung cancer: the implications of impaired extracellular superoxide dismutase and catalase antioxidant systems, Lung Cancer60 (2008), 277-84.
22.
CoskunE., JarugaP., ReddyP.T., and DizdarogluM., Extreme Expression of DNA Repair Protein Apurinic/Apyrimidinic Endonuclease 1 (APE1) in Human Breast Cancer As Measured by Liquid Chromatography and Isotope Dilution Tandem Mass Spectrometry, Biochemistry54 (2015), 5787-90.
23.
WooJ., ParkH., SungS.H., MoonB.I., SuhH., and LimW., Prognostic value of human apurinic/apyrimidinic endonuclease 1 (APE1) expression in breast cancer, PLoS One9 (2014), e99528.
24.
LiZ., QingY., GuanW., LiM., PengY., ZhangS., XiongY., and WangD., Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy, Cancer Chemother Pharmacol74 (2014), 777-86.
25.
SakS.C., HarndenP., JohnstonC.F., PaulA.B., and KiltieA.E., APE1 and XRCC1 protein expression levels predict cancer-specific survival following radical radiotherapy in bladder cancer, Clin Cancer Res11 (2005), 6205-11.
26.
RuiterD.J., FerrierC.M., van MuijenG.N., Henzen-LogmansS.C., KennedyS., KramerM.D., NielsenB.S., and SchmittM., Quality control of immunohistochemical evaluation of tumour-associated plasminogen activators and related components. European BIOMED-1 Concerted Action on Clinical Relevance of Proteases in Tumour Invasion and Metastasis, Eur J Cancer34 (1998), 1334-40.
27.
CohenJ.G., WhiteM., CruzA., and Farias-EisnerR., In 2014, can we do better than CA125 in the early detection of ovarian cancer? World J Biol Chem5 (2014), 286-300.
28.
RatnerE.S., SartorelliA.C., and LinZ.P., Poly (ADP-ribose) polymerase inhibitors: On the horizon of tailored and personalized therapies for epithelial ovarian cancer, Curr Opin Oncol24 (2012), 564-71.
29.
ZhangY., WangJ., XiangD., WangD., and XinX., Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE1/Ref-1) in human ovarian cancer and indentification of the therapeutic potential of APE1/Ref-1 inhibitor, Int J Oncol35 (2009), 1069-79.
30.
FishelM.L., HeY., ReedA.M., Chin-SinexH., HutchinsG.D., MendoncaM.S., and KelleyM.R., Knockdown of the DNA repair and redox signaling protein Ape1/Ref-1 blocks ovarian cancer cell and tumor growth, DNA Repair (Amst)7 (2008), 177-86.
31.
JiangY., ZhouS., SanduskyG.E., KelleyM.R., and FishelM.L., Reduced expression of DNA repair and redox signaling protein APE1/Ref-1 impairs human pancreatic cancer cell survival, proliferation, and cell cycle progression, Cancer Invest28 (2010), 885-95.
32.
ZhangY., WangJ., XiangD., WangD., and XinX., Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE1/Ref-1) in human ovarian cancer and indentification of the therapeutic potential of APE1/Ref-1 inhibitor, Int J Oncol35 (2009), 1069-79.
33.
MontaldiA.P., GodoyP.R., Sakamoto-HojoE.T., APE1/REF-1 down-regulation enhances the cytotoxic effects of temozolomide in a resistant glioblastoma cell line, Mutation Research793 (2015), 19-29.
34.
JohnsonJ.L., LowellB.C., RyabininaO.P., LloydR.S., and McCulloughA.K., TAT-mediated delivery of a DNA repair enzyme to skin cells rapidly initiates repair of UV-induced DNA damage, J Invest Dermatol131 (2011), 753-61.
35.
GedikC.M., and CollinsA.R., Comparison of effects of fostriecin, novobiocin, and camptothecin, inhibitors of DNA topoisomerases, on DNA replication and repair in human cells, Nucleic Acids Res18 (1990), 1007-13.
36.
FerraraL., and KmiecE.B., Camptothecin enhances the frequency of oligonucleotide-directed gene repair in mammalian cells by inducing DNA damage and activating homologous recombination, Nucleic Acids Res32 (2004), 5239-48.
37.
Singh-GuptaV., JoinerM.C., RunyanL., YunkerC.K., SarkarF.H., MillerS., GadgeelS.M., KonskiA.A., and HillmanG.G., Soy isoflavones augment radiation effect by inhibiting APE1/Ref-1 DNA repair activity in non-small cell lung cancer, J Thorac Oncol6 (2011), 688-98.
